AngioDynamics, Inc. (NASDAQ:ANGO) has been given a consensus recommendation of “Hold” by the nine analysts that are currently covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $20.00.

ANGO has been the subject of a number of recent analyst reports. BidaskClub downgraded shares of AngioDynamics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 12th. Raymond James downgraded shares of AngioDynamics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, July 11th. Zacks Investment Research downgraded shares of AngioDynamics from a “buy” rating to a “hold” rating in a research report on Tuesday, June 5th. Finally, Canaccord Genuity reiterated a “hold” rating and set a $20.00 price target on shares of AngioDynamics in a research report on Thursday, July 12th.

Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. lifted its position in shares of AngioDynamics by 7.3% during the 2nd quarter. BlackRock Inc. now owns 5,478,788 shares of the medical instruments supplier’s stock valued at $121,848,000 after acquiring an additional 374,834 shares during the period. Janus Henderson Group PLC lifted its position in shares of AngioDynamics by 0.3% during the 2nd quarter. Janus Henderson Group PLC now owns 1,802,894 shares of the medical instruments supplier’s stock valued at $40,096,000 after acquiring an additional 6,027 shares during the period. Wells Fargo & Company MN lifted its position in shares of AngioDynamics by 6.7% during the 1st quarter. Wells Fargo & Company MN now owns 1,214,928 shares of the medical instruments supplier’s stock valued at $20,957,000 after acquiring an additional 76,767 shares during the period. Northern Trust Corp lifted its position in shares of AngioDynamics by 0.8% during the 2nd quarter. Northern Trust Corp now owns 1,209,647 shares of the medical instruments supplier’s stock valued at $26,903,000 after acquiring an additional 9,119 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in shares of AngioDynamics by 958.2% during the 1st quarter. JPMorgan Chase & Co. now owns 895,414 shares of the medical instruments supplier’s stock worth $15,447,000 after purchasing an additional 810,794 shares in the last quarter. Institutional investors own 98.18% of the company’s stock.

NASDAQ:ANGO traded down $0.11 during mid-day trading on Friday, reaching $23.31. The stock had a trading volume of 3,225 shares, compared to its average volume of 138,552. The company has a quick ratio of 2.08, a current ratio of 2.93 and a debt-to-equity ratio of 0.16. The company has a market cap of $842.72 million, a P/E ratio of 31.77 and a beta of 0.93. AngioDynamics has a twelve month low of $15.16 and a twelve month high of $24.24.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Wednesday, July 11th. The medical instruments supplier reported $0.20 EPS for the quarter, missing the Zacks’ consensus estimate of $0.21 by ($0.01). The firm had revenue of $88.30 million during the quarter, compared to analyst estimates of $89.02 million. AngioDynamics had a net margin of 4.74% and a return on equity of 5.21%. The business’s quarterly revenue was up 1.6% compared to the same quarter last year. analysts expect that AngioDynamics will post 0.86 EPS for the current year.

About AngioDynamics

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Featured Story: What Factors Can Affect Return on Equity?

Analyst Recommendations for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.